journal article·2026-03Open access

IL1R2 Marks and Sorts a Spermatogonial Stem Cell Population Critical for Restoring Spermatogenesis Upon Interruption in Mammals

Pengyu Li, Zexuan Zhang, Zihan Xie, Cheng Jin, Zhipeng Wang, Changwei Yuan, Jun Zhu, Jielin Tang, Mengzhen Li, Dingfeng Zou, Xinyu Mang, Jun Liu, Dingyao Chen, Qi Geng, Yan Lu, Ning Zhang, Shiying Miao, Jing Peng, Kai Li, Wei Song

Advanced Science· Volume 13· Issue 13

Abstract

ABSTRACT Self‐renewal and differentiation of spermatogonial stem cells (SSCs) are critical for sustaining spermatogenesis in adult mammals. However, SSCs are highly heterogeneous, comprising a complex array of subpopulations whose identities and dynamic transitions remain greatly underappreciated. Through in silico analysis, we identified IL1R2 as a surface marker specific to the SSC subpopulation. IL1R2 enables the specific sorting of functionally active SSCs in both human and mouse. Il1r2 CreERT2/+ Rosa26 mTmG/+ mice allowed us to pulse‐label and trace the lineage of Il1r2 ‐expressing cells. We confirmed that IL1R2 + SSCs support spermatogenesis via both self‐renewal and differentiation. Following spermatogenic disruption, IL1R2 + SSCs are reactivated for proliferation via the PI3K‐AKT‐mTORC1 pathway to replenish the SSC pool. Importantly, we demonstrated that PI3K‐AKT‐mTORC1 agonists can effectively enhance the recovery of spermatogenesis upon disruption. These findings highlight a promising therapeutic strategy to mitigate chemotherapy‐induced infertility.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Sperm and Testicular Function · Reproductive Biology and Fertility · Pluripotent Stem Cells Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biochemistry and Molecular Biology State Key Laboratory of Common Mechanism Research for Major Diseases Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College Beijing 100005 China

Andrology Center, Department of Urology Peking University First Hospital Beijing 100034 China

Beijing Hsienseng Medical Technology Beijing China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (47)

Show source-provided references
1. 10.1095/biolreprod.103.01702010.1095/biolreprod.103.017020 ↗
2. 10.1007/s00018‐019‐03201‐610.1007/s00018‐019‐03201‐6 ↗
3. 10.1093/humrep/der35710.1093/humrep/der357 ↗
4. 10.1038/s41467‐018‐04827‐z10.1038/s41467‐018‐04827‐z ↗
5. 10.1016/j.devcel.2018.07.02510.1016/j.devcel.2018.07.025 ↗
6. 10.1242/dev.14692810.1242/dev.146928 ↗
7. 10.1172/jci7594310.1172/jci75943 ↗
8. 10.7554/eLife.85380.310.7554/eLife.85380.3 ↗
9. 10.1095/biolreprod.116.14422010.1095/biolreprod.116.14422010.1095/biolreprod.116.14422010.1095/biolreprod.116.144220 ↗
10. 10.7554/eLife.4335210.7554/eLife.43352 ↗
11. 10.1126/science.117264510.1126/science.1172645 ↗
12. 10.1016/j.celrep.2021.10987510.1016/j.celrep.2021.10987510.1016/j.celrep.2021.10987510.1016/j.celrep.2021.109875 ↗
13. 10.1016/j.stemcr.2017.01.00610.1016/j.stemcr.2017.01.006 ↗
14. 10.1038/srep0617510.1038/srep06175 ↗
15. 10.1038/srep1759410.1038/srep1759410.1038/srep1759410.1038/srep17594 ↗
16. 10.1126/science.118286810.1126/science.1182868 ↗
17. 10.1084/jem.2016137110.1084/jem.20161371 ↗
18. 10.1038/s41467‐022‐30130‐z10.1038/s41467‐022‐30130‐z ↗
19. 10.1016/j.stem.2014.01.01910.1016/j.stem.2014.01.019 ↗
20. 10.1016/j.stemcr.2022.02.01710.1016/j.stemcr.2022.02.017 ↗
21. 10.1016/j.celrep.2018.10.02610.1016/j.celrep.2018.10.026 ↗
22. 10.1126/sciadv.abq317310.1126/sciadv.abq317310.1126/sciadv.abq317310.1126/sciadv.abq3173 ↗
23. 10.1210/endo.140.12.717210.1210/endo.140.12.7172 ↗
24. 10.3390/cells1009240310.3390/cells10092403 ↗
25. 10.1242/dev.00300410.1242/dev.003004 ↗
26. 10.1096/fj.202301664R10.1096/fj.202301664R10.1096/fj.202301664R10.1096/fj.202301664R ↗
27. 10.1038/s41392-023-01608-z10.1038/s41392-023-01608-z ↗
28. 10.1016/j.bcp.2019.11375210.1016/j.bcp.2019.11375210.1016/j.bcp.2019.11375210.1016/j.bcp.2019.113752 ↗
29. 10.1016/j.pestbp.2018.12.00510.1016/j.pestbp.2018.12.005 ↗
30. 10.1038/s41419-023-05778-010.1038/s41419-023-05778-0 ↗
31. 10.1158/1078‐0432.Ccr‐11‐208810.1158/1078‐0432.Ccr‐11‐2088 ↗
32. 10.3892/mmr.2011.68210.3892/mmr.2011.682 ↗
33. 10.1089/ten.TEB.2012.067210.1089/ten.TEB.2012.0672 ↗
34. 10.1016/j.intimp.2023.11024710.1016/j.intimp.2023.11024710.1016/j.intimp.2023.11024710.1016/j.intimp.2023.110247 ↗
35. 10.1093/humrep/dep03310.1093/humrep/dep03310.1093/humrep/dep03310.1093/humrep/dep033 ↗
36. 10.1016/j.stemcr.2017.12.00910.1016/j.stemcr.2017.12.009 ↗
37. 10.1016/j.ydbio.2004.12.00610.1016/j.ydbio.2004.12.006 ↗
38. 10.1038/s41422‐018‐0099‐210.1038/s41422‐018‐0099‐2 ↗
39. 10.3390/ijms2121826910.3390/ijms21218269 ↗
40. 10.4049/jimmunol.140215510.4049/jimmunol.1402155 ↗
41. 10.3389/fendo.2022.85348210.3389/fendo.2022.85348210.3389/fendo.2022.85348210.3389/fendo.2022.853482 ↗
42. 10.1093/humrep/der02610.1093/humrep/der026 ↗
43. 1,5‐dicaffeoylquinic Acid Protects Primary Neurons from Amyloid β 1‐42‐induced Apoptosis via PI3K/Akt Signaling Pathway
44. 10.7150/thno.8253510.7150/thno.82535 ↗
45. Quantitative MRI Establishes the Efficacy of PI3K Inhibitor (GDC‐0941) Multi‐treatments in PTEN‐deficient Mice Lymphoma
46. 10.1371/journal.pone.004341810.1371/journal.pone.004341810.1371/journal.pone.004341810.1371/journal.pone.0043418 ↗
47. 10.1016/s0091‐679x(08)00004‐610.1016/s0091‐679x(08)00004‐6 ↗